Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. Glaukos is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Glaukos developed Micro Invasive Glaucoma Surgery to serve as an alternative to the traditional glaucoma treatment and management paradigms. The company's iStent platform is the first MIGS device in the United States. Glaukos markets its products through direct sales force in the United States and other countries. It has distribution partners in Europe, the Asia Pacific, Latin America, and internationally.
| Revenue (Most Recent Fiscal Year) | $383.48M |
| Net Income (Most Recent Fiscal Year) | $-146.37M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 13.79 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 7.30 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -30.40% |
| Net Margin (Trailing 12 Months) | -31.40% |
| Return on Equity (Trailing 12 Months) | -10.66% |
| Return on Assets (Trailing 12 Months) | -8.06% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.49 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.62 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.09 |
| Inventory Turnover (Trailing 12 Months) | 1.68 |
| Book Value per Share (Most Recent Fiscal Quarter) | $13.91 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.22 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.86 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.37 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 57.14M |
| Free Float | 53.48M |
| Market Capitalization | $5.58B |
| Average Volume (Last 20 Days) | 0.85M |
| Beta (Past 60 Months) | 0.80 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 99.04% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |